We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Vienna, Austria

ESTRO 2023

Session Item

Sunday
May 14
15:15 - 16:30
Strauss 2
Supportive care and toxicity assessment in brachytherapy
Luca Tagliaferri, Italy;
Magdalena Stankiewicz, Poland
The modern oncology is characterized by a personalized approach and the physicians, in the daily practice, should propose to the patients the best treatments considering not only the classical oncological outcome such as local control, disease free survival and overall survival but also the quality of life after treatment, especially in terms of late side effects. In this symposium toxicity assessment and supportive care before, during and after brachytherapy procedures (Interventional Radiotherapy) will be discussed. The lectures will be focused on different tumors: gynecological, breast, head & neck and skin cancers and different strategies to reduce toxicity and improve patient compliance will be discussed in multidisciplinary approach involving not only interventional radiation oncologists but also psychologist. In addition, the role of new technologies to improve patients’ psychological profile will be highlight
Symposium
Brachytherapy
15:51 - 16:09
Supportive care and toxicity assessment in brachytherapy - Focus on head & neck and skin cancers
Agata Rembielak, United Kingdom
SP-0544

Abstract

Supportive care and toxicity assessment in brachytherapy - Focus on head & neck and skin cancers
Authors:

Agata Rembielak1

1The Christie NHS Foundation Trust and The University of Manchester, Clinical Oncology, Manchester, United Kingdom

Show Affiliations
Abstract Text

Patients with head and neck or skin (NHS) cancers face multiple physical and psychosocial challenges triggered by cosmetic or functional deficit. Many skin cancers are diagnosed in the head and neck region and hence are regarded as cosmetic and functional sensitive. The symptoms that patients with HNS cancers experience are related to cancer itself and / or their anticancer treatment. In HNS cancers among available treatment options brachytherapy (BT) has been proven to offer favourable cosmesis and functional outcomes in addition to excellent cure rates.

All professionals caring for patients with HNS cancer should assess supportive care needs. In BT ideally such assessment should be done at the initial consultation and subsequently reviewed at planning, during treatment and at follow-up. In such way the supportive care can be initiated promptly, including the involvement from specialist supportive care professionals, if required.

The talk will cover the role of supportive care in the management of patients with HNS cancers with particular emphasis on BT. It will also discuss toxicity assessment in BT for HNS cancers and the role of quality of life (QoL) and patient reported outcome measures (PROMs) in this group of patients. There is a lack of BT specific toxicity assessment scale(s) that can serve as the gold standard. Given the additional function preservation benefit with BT over surgery and in some cases over external bean radiotherapy, there is a need for such BT orientated scales.